{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T07:48:52Z","timestamp":1789199332393,"version":"build-2803163510"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2008]]},"DOI":"10.1016\/j.clinthera.2008.12.002","type":"journal-article","created":{"date-parts":[[2009,3,11]],"date-time":"2009-03-11T08:40:22Z","timestamp":1236760822000},"page":"2181-2190","source":"Crossref","is-referenced-by-count":22,"special_numbering":"P2","title":["Angiotensin II receptor blockers in the treatment of the cardiovascular disease continuum"],"prefix":"10.1016","volume":"30","author":[{"given":"Steven G.","family":"Chrysant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2008.12.002_bib1","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/0002-8703(91)90694-D","article-title":"Resolved and unresolved issues in the prevention and treatment of coronary artery disease: A workshop consensus statement","volume":"121","author":"Dzau","year":"1991","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinthera.2008.12.002_bib2","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1161\/CIRCULATIONAHA.106.655688","article-title":"The cardiovascular disease continuum validated: Clinical evidence of improved patient outcomes: Part 1: Pathophysiology and clinical trial evidence (Risk factors through stable coronary artery disease)","volume":"114","author":"Dzau","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2008.12.002_bib3","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.diabres.2004.06.010","article-title":"Prevention of type 2 diabetes by lifestyle intervention: A Japanese trial in IGT males","volume":"67","author":"Kosaka","year":"2005","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.clinthera.2008.12.002_bib4","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1007\/s001250051024","article-title":"No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malm\u00f6 Preventive Trial with diet and exercise","volume":"41","author":"Eriksson","year":"1998","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2008.12.002_bib5","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/S0140-6736(02)08905-5","article-title":"Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial","volume":"359","author":"Chiasson","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2008.12.002_bib6","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/archinte.165.12.1410","article-title":"Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: Results of prospectively designed overviews of randomized trials","volume":"165","author":"Turnbull","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2008.12.002_bib7","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/bmj.39548.738368.BE","article-title":"Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: Meta-analysis of randomised trials","volume":"336","author":"Turnbull","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2008.12.002_bib8","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1093\/eurheartj\/ehn427","article-title":"Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials","volume":"29","author":"Turnbull","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2008.12.002_bib9","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1097\/HJH.0b013e32814a5ae5","article-title":"Does a change in angiotensin II formation caused by antihypertensive drugs affect the risk of stroke? A meta-analysis of trials according to treatment with potentially different effects on angiotensin II","volume":"25","author":"Boutitie","year":"2007","journal-title":"J Hypertens"},{"key":"10.1016\/j.clinthera.2008.12.002_bib10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1161\/01.HYP.0000252676.46043.18","article-title":"Prevalence, awareness, treatment, and control of hypertension among United States adults 1999\u20132004","volume":"49","author":"Ong","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2008.12.002_bib11","first-page":"1903","article-title":"Age-specific rele vance of usual blood pressure to vascular mortality: A meta-analysis of individual data from one million adults in 61 prospective studies [published correction appears in Lancet. 2003;361:1060]","volume":"360","author":"Lewington","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2008.12.002_bib12","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1291\/hypres.28.385","article-title":"Blood pressure reduction and cardiovascular prevention: An update including the 2003\u20132004 secondary prevention trials","volume":"28","author":"Staessen","year":"2005","journal-title":"Hypertens Res"},{"key":"10.1016\/j.clinthera.2008.12.002_bib13","first-page":"951","article-title":"Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system [published correction appears in J Hypertens. 2007;25:1524]","volume":"25","author":"Turnbull","year":"2007","journal-title":"J Hypertens"},{"key":"10.1016\/j.clinthera.2008.12.002_bib14","doi-asserted-by":"crossref","first-page":"12061252","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2008.12.002_bib15","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/HJH.0b013e3281fc975a","volume":"25","author":"Mancia","year":"2007","journal-title":"J Hypertens"},{"key":"10.1016\/j.clinthera.2008.12.002_bib16","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/00004872-200104000-00020","article-title":"Risk assessment and treatment benefit in intensively treated hypertensive patients of the Hypertension Optimal Treatment (HOT) Study","volume":"19","author":"Zanchetti","year":"2001","journal-title":"J Hypertens"},{"key":"10.1016\/j.clinthera.2008.12.002_bib17","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/00004872-200404000-00029","article-title":"Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial","volume":"22","author":"Staessen","year":"2004","journal-title":"J Hypertens"},{"key":"10.1016\/j.clinthera.2008.12.002_bib18","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa060838","article-title":"Feasibility of treating prehypertension with an angiotensin-receptor blocker","volume":"354","author":"Julius","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2008.12.002_bib19","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1097\/HJH.0b013e3282ff8864","article-title":"The PHARAO study: Prevention of hypertension with the angiotensinconverting enzyme inhibitor ramipril in patients with high-normal blood pressure: A prospective, randomized, controlled prevention trial of the German Hypertension League","volume":"26","author":"L\u00fcders","year":"2008","journal-title":"J Hypertens"},{"key":"10.1016\/j.clinthera.2008.12.002_bib20","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/0735-1097(95)00606-0","article-title":"Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials","volume":"27","author":"Moser","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2008.12.002_bib21","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1097\/HJH.0b013e3282fe1d3d","article-title":"Development of heart failure in recent hypertension trials","volume":"26","author":"Tocci","year":"2008","journal-title":"J Hypertens"},{"key":"10.1016\/j.clinthera.2008.12.002_bib22","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/0003-4819-138-1-200301070-00006","article-title":"Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study","volume":"138","author":"Haider","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2008.12.002_bib23","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1053\/hj.1998.v135.86971","article-title":"Vascular remodeling: The role of angiotensin-converting enzyme inhibitors","volume":"135","author":"Chrysant","year":"1998","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinthera.2008.12.002_bib24","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/01.hjh.0000165623.72310.dd","article-title":"The cardiovascular continuum and renin-angiotensinaldosterone system blockade","volume":"23","author":"Dzau","year":"2005","journal-title":"J Hypertens Suppl"},{"key":"10.1016\/j.clinthera.2008.12.002_bib25","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1161\/01.CIR.0000140265.21608.8E","article-title":"Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation","volume":"110","author":"Fliser","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2008.12.002_bib26","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1161\/CIRCULATIONAHA.105.595496","article-title":"Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: Principal results of the Conduit Artery Function Evaluation (CAFE) Study","volume":"113","author":"Williams","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2008.12.002_bib27","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mor tality in the Losartan Intervention For Endpoint reduction in hypertension (LIFE): A randomised trial against atenolol","volume":"359","author":"Dahl\u00f6f","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2008.12.002_bib28","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1524-6175.2004.03449.x","article-title":"Clinical experience with angiotensin receptor blockers with particular reference to valsartan","volume":"6","author":"Chrysant","year":"2004","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.clinthera.2008.12.002_bib29","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/00005344-200312000-00005","article-title":"Long-term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension: The Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA)","volume":"42","author":"Malmqvist","year":"2003","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.clinthera.2008.12.002_bib30","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1161\/01.CIR.98.19.2037","article-title":"Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension","volume":"98","author":"Th\u00fcrmann","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2008.12.002_bib31","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1097\/00004872-200211000-00030","article-title":"Comparative effects of cande sartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: The Candesartan Assessment in the Treatment of Cardiac Hypertrophy (CATCH) Study","volume":"20","author":"Cuspidi","year":"2002","journal-title":"J Hypertens"},{"key":"10.1016\/j.clinthera.2008.12.002_bib32","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1358\/dot.2004.40.9.850498","article-title":"Stroke prevention with losartan in the context of other antihypertensive drugs","volume":"40","author":"Chrysant","year":"2004","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.clinthera.2008.12.002_bib33","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1001\/jama.288.12.1491","article-title":"Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: A Losartan Intervention for Endpoint Reduction (LIFE) substudy","volume":"288","author":"Kjeldsen","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2008.12.002_bib34","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/00004872-200305000-00011","article-title":"The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized doubleblind intervention trial","volume":"21","author":"Lithell","year":"2003","journal-title":"J Hypertens"},{"key":"10.1016\/j.clinthera.2008.12.002_bib35","first-page":"1175","article-title":"Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: The Study on Cognition and Prognosis in the Elderly (SCOPE)","volume":"44","author":"Papademetriou","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2008.12.002_bib36","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1161\/01.STR.0000166048.35740.a9","article-title":"Morbidityand Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: Principal results of a prospective randomized controlled study (MOSES)","volume":"36","author":"Schrader","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.clinthera.2008.12.002_bib37","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/S0140-6736(07)60669-2","article-title":"Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): A randomized, openlabel, blinded endpoint morbiditymortality study","volume":"369","author":"Mochizuki","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2008.12.002_bib38","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1524-6175.2007.06602.x","article-title":"The pathophysiologic role of the brain renin-angiotensin system in stroke protection: Clinical implications","volume":"9","author":"Chrysant","year":"2007","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.clinthera.2008.12.002_bib39","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.CIR.0000024416.33113.0A","article-title":"Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect","volume":"106","author":"Viberti","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2008.12.002_bib40","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2008.12.002_bib41","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2008.12.002_bib42","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2008.12.002_bib43","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.amjhyper.2006.10.002","article-title":"Effect of telmisartan-amloclipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria","volume":"20","author":"Fogari","year":"2007","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.clinthera.2008.12.002_bib44","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2008.12.002_bib45","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1161\/01.HYP.0000161880.59963.da","article-title":"Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension","volume":"45","author":"Doulton","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2008.12.002_bib46","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2008.12.002_bib47","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: An American Heart Association\/National Heart, Lung, and Blood Institute scientific statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2008.12.002_bib48","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1161\/CIRCULATIONAHA.108.189702","volume":"118","author":"Kumanyika","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2008.12.002_bib49","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1161\/01.CIR.100.13.1481","article-title":"Assessment of cardiovascular risk by use of multiple risk-factor assessment equations: A statement for healthcare professionals from the American Heart Association and the American College ofCardiology","volume":"100","author":"Grundy","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2008.12.002_bib50","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1161\/01.CIR.0000133321.00456.00","article-title":"Preventing cancer, cardiovascular disease, and diabetes: A common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association","volume":"109","author":"Eyre","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2008.12.002_bib51","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1097\/HJH.0b013e328308da55","article-title":"Implications of persistent prehypertension for ageing-related changes in left ventricular geometry and function: The MONICA\/KORA Augsburg study","volume":"26","author":"Markus","year":"2008","journal-title":"J Hypertens"},{"key":"10.1016\/j.clinthera.2008.12.002_bib52","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction","volume":"355","author":"Owan","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2008.12.002_bib53","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1001\/jama.300.4.431","article-title":"Heart failure with preserved ejection fraction: Treat now by treating comorbidities","volume":"300","author":"Shah","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2008.12.002_bib54","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2008.12.002_bib55","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa0801369","article-title":"Treatment of hypertension in patients 80 years of age or older","volume":"358","author":"Beckett","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2008.12.002_bib56","doi-asserted-by":"crossref","first-page":"901","DOI":"10.7326\/0003-4819-139-11-200312020-00008","article-title":"Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE study","volume":"139","author":"Wachtell","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2008.12.002_bib57","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1524-6175.2007.06395.x","article-title":"Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension","volume":"9","author":"Giles","year":"2007","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.clinthera.2008.12.002_bib58","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.amjhyper.2007.02.017","article-title":"Time to achieve blood-pressure goal: Influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy","volume":"20","author":"Weir","year":"2007","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.clinthera.2008.12.002_bib59","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.clinthera.2008.04.002","article-title":"The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study","volume":"30","author":"Chrysant","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2008.12.002_bib60","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1001\/archinte.163.5.525","article-title":"Management of high blood pressure in African Americans: Consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks","volume":"163","author":"Douglas","year":"2003","journal-title":"Arch Intern Med"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291808004165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291808004165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T21:41:09Z","timestamp":1583962869000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291808004165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008]]},"references-count":60,"alternative-id":["S0149291808004165"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2008.12.002","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2008]]}}}